Liminatus Pharma, Inc. Class A Common Stock
Liminatus Pharma, Inc. is an immuno-oncology firm, currently in its clinical development phase, dedicated to pioneering new treatments for cancer. The company's headquarters are located in La Palma, California.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | -2.96 | $0 | -$969,999 |
| 2026 Q1 | -2.37 | $0 | -$2M |
| 2025 Q4 | -15.00 | $0 | -$386,850 |
| 2025 Q3 | -3.38 | $0 | -$613,720 |
| 2025 Q2 | 0.24 | $0 | -$9M |
| 2025 Q1 | -127.50 | $0 | -$159,393 |
| 2024 Q4 |
| -6.00 |
| $0 |
| -$140,660 |
| 2024 Q3 | -4.48 | $0 | -$729,360 |